‘One Health’ for the people of Hong Kong and the world

Kok, Kin‐Hang; Tang, Ho Man; Jin, Dong-Yan

doi:10.1007/s11427-012-4408-6

Sci. China Life Sci.

2012

DOI: 10.1007/s11427-012-4408-6

|View full text |Cite

‘One Health’ for the people of Hong Kong and the world

Kin‐Hang Kok

Ho Man Tang

Dong-Yan Jin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imatinib mesylate (IM) is a targeted molecular drug that serves as frontline therapy for all phases of CML for newly diagnosed patients that works by binding to the tyrosine kinase domain of BCR-ABL and inhibiting its function [3][4][5]. Although high response rates are observed for CML patients who undergo IM treatment, a significant number of patients develop primary or acquired resistance to IM [1,2].…”

mentioning

confidence: 99%

Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations

Lai

et al. 2015

Sci. China Life Sci.

View full text Add to dashboard Cite

Diversity in the T cell receptor (TCR) repertoire provides a miniature defense ability for the T cell immune system that may be related to tumor initiation and progression. Understanding the T cell immune status of leukemia patients is critical for establishing specific immunotherapies. Previous studies have reported abnormal TCR repertoires and clonally expanded TCR V T cells in chronic myeloid leukemia in chronic phase (CP-CML). In this study, we investigated the distribution and clonality of the TCR V repertoire in 4 cases with imatinib-resistant CML in blast crisis (BC-CML) with abelson murine leukemia viral oncogene homolog 1 (ABL1) kinase domain mutations (KDMs). Examination of TCR V expression and clonality was performed by reverse transcription-polymerase chain reaction (RT-PCR) and GeneScan analysis. Significantly skewed TCR V repertoires were observed in BC-CML patients with different KDMs, and 4 to 8 oligoclonally expanded TCR V subfamilies could be identified in each sample. Intriguingly, a relatively highly expanded V9 clone with the same length as complementarity-determining region 3 (CDR3) (139 bp) was found in all three CML patients in lymphoid blast crisis (LBC-CML) who had different KDMs, but the clone was not detected in the only CML patient in myeloid blast crisis (MBC-CML). In conclusion, restricted TCR V repertoire expression and decreased clone complexity was a general phenomenon observed in the BC-CML patients with different KDMs, indicating the T-cell immunodeficiency of these patients. In addition, clonally expanded V9 T cell clones may indicate a specific immune response to leukemia-associated antigens in LBC-CML patients.T cell repertoire, chronic myeloid leukemia, blast crisis, imatinib resistance, BCR-ABL mutation Citation:

show abstract

mentioning

confidence: 99%

Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations

Lai

et al. 2015

Sci. China Life Sci.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

‘One Health’ for the people of Hong Kong and the world

Cited by 1 publication

References 9 publications

Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations

Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations

Contact Info

Product

Resources

About